J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text HTML] [Full Text PDF] （in Japanese / 477KB） [Members Only]

J.Jpn. Surg. Soc.. 108(1): 30-34, 2007

Feature topic

INFORMED CONSENT FOR PATIENTS WITH PANCREATIC CANCER

Department of Surgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan

Ryoko Sasaki, Tatsuya Oda, Shinji Hashimoto, Kiyoshi Fukunaga, Tadashi Kondo, Hideo Terashima, Masayoshi Yamamoto, Satoshi Inagawa, Kazuhiko Yanagisawa, Nobuhiro Ohkohchi

Pancreatic cancer is an intractable malignancy with the poorest prognosis among digestive tract cancers. It is important when we obtain informed consent (IC) from patients with pancreatic cancer and their families to convey sufficiently that pancreatic cancer is intractable and provide support to help patients maintain a positive attitude toward treatment. Although the efficacy of chemo (radiation) therapy in pancreatic cancer is still unclear, the progress of various clinical trials on postoperative adjuvant therapy centered on gemcitabine hydrochloride, and chemo (radiation) therapy for unresectable tumors has raised expectations in recent years. To enable each individual patient to select the optimal treatment based on his or her personal outlook on life, it is important to obtain IC in good faith through the accurate diagnosis of pancreatic cancer and the use of the latest treatment information.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.